Docetaxel

BreastfeedingGeriatricPediatric
  • TRADE NAME: Taxotere (Sanofi-Aventis)
  • INDICATIONS: Metastatic breast cancer, non-small cell lung cancer; with prednisone in hormone refractory prostate cancer; with cisplatin and fluorouracil for gastric adenocarcinoma and squamous cell carcinoma of the head and neck
  • CLASS: Antineoplastic, Taxane
  • HALF-LIFE: 11–18 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Alcohol, Aldesleukin, Anthracyclines, Antifungals, Aprepitant, BCG Vaccine, Conivaptan, Cyclosporine, CYP3A4 inhibitors or inducers, Dasatinib, Deferasirox, Denosumab, Echinacea, Erythromycin, Itraconazole, Ketoconazole, Lapatinib, Leflunomide, Natalizumab, P-glycoprotein inhibitors or inducers, Pimecrolimus, Prednisone, Ritonavir, Sipuleucel-T, Sorafenib, St John's Wort, Tacrolimus, Thalidomide, Trastuzumab, Vaccines, Voriconazole

PREGNANCY CATEGORY: D

Contra-indicated in patients with hypersensitivity to docetaxel or polysorbate 80, or with neutrophil counts of <1500 cells/mm3.

TOXIC DEATHS, HEPATOTOXICITY, NEUTROPENIA, HYPERSENSITIVITY REACTIONS, and FLUID RETENTION

See full prescribing information for complete boxed warning.

Our database has 185 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN.
HAIR.
NAILS.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
LOCAL.
NEUROMUSCULAR/SKELETAL.
OCULAR.
RENAL.
RESPIRATORY.
OTHER.


Page last updated 07/05/2020

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top